Shijiazhuang Yiling Pharmaceutical's (SHE:002603) unit, Anyang Hengshui Pharmaceutical, received a certificate of suitability from Europe's drug regulator for the Anastrozole active pharmaceutical ingredient, according to a Shenzhen bourse filing on Tuesday.
The API is a treatment for breast cancer in postmenopausal women.